vs
Side-by-side financial comparison of ICU MEDICAL INC (ICUI) and Verisk Analytics (VRSK). Click either name above to swap in a different company.
Verisk Analytics is the larger business by last-quarter revenue ($778.8M vs $540.7M, roughly 1.4× ICU MEDICAL INC). Verisk Analytics runs the higher net margin — 25.3% vs -2.9%, a 28.2% gap on every dollar of revenue. On growth, Verisk Analytics posted the faster year-over-year revenue change (5.9% vs -14.1%). Verisk Analytics produced more free cash flow last quarter ($276.1M vs $36.0M). Over the past eight quarters, Verisk Analytics's revenue compounded faster (5.2% CAGR vs -2.3%).
ICU Medical, Inc. is a medical technology company based in San Clemente, California. ICU Medical products are designed to prevent bloodstream infections and protect healthcare workers from exposure to infectious diseases or hazardous drugs. ICU Medical product line includes intravenous therapy (IV) products, pumps, needle-free vascular access devices, custom infusion sets, closed system hazardous drug handling devices and systems, sensor catheters, needle-free closed blood sampling systems, a...
Verisk AnalyticsVRSKEarnings & Financial Report
Verisk Analytics, Inc. is an American multinational data analytics and risk assessment firm based in Jersey City, New Jersey, with clients in insurance, government, and risk management sectors. The company uses proprietary data sets and industry expertise to provide predictive analytics and decision support consultations in areas including fraud prevention, actuarial science, insurance coverage, fire protection, catastrophe and weather risk, and data management.
ICUI vs VRSK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $540.7M | $778.8M |
| Net Profit | $-15.7M | $197.2M |
| Gross Margin | 37.5% | 69.7% |
| Operating Margin | 1.0% | 40.3% |
| Net Margin | -2.9% | 25.3% |
| Revenue YoY | -14.1% | 5.9% |
| Net Profit YoY | 34.0% | -6.3% |
| EPS (diluted) | $-0.63 | $1.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $540.7M | $778.8M | ||
| Q3 25 | $537.0M | $768.3M | ||
| Q2 25 | $548.9M | $772.6M | ||
| Q1 25 | $604.7M | $753.0M | ||
| Q4 24 | $629.8M | $735.6M | ||
| Q3 24 | $589.1M | $725.3M | ||
| Q2 24 | $596.5M | $716.8M | ||
| Q1 24 | $566.7M | $704.0M |
| Q4 25 | $-15.7M | $197.2M | ||
| Q3 25 | $-3.4M | $225.5M | ||
| Q2 25 | $35.3M | $253.3M | ||
| Q1 25 | $-15.5M | $232.3M | ||
| Q4 24 | $-23.8M | $210.4M | ||
| Q3 24 | $-33.0M | $220.1M | ||
| Q2 24 | $-21.4M | $308.1M | ||
| Q1 24 | $-39.5M | $219.6M |
| Q4 25 | 37.5% | 69.7% | ||
| Q3 25 | 37.4% | 70.1% | ||
| Q2 25 | 37.9% | 70.3% | ||
| Q1 25 | 34.7% | 69.3% | ||
| Q4 24 | 36.1% | 68.7% | ||
| Q3 24 | 34.8% | 69.2% | ||
| Q2 24 | 34.8% | 69.4% | ||
| Q1 24 | 32.7% | 67.6% |
| Q4 25 | 1.0% | 40.3% | ||
| Q3 25 | 2.6% | 45.0% | ||
| Q2 25 | 1.9% | 45.9% | ||
| Q1 25 | 2.1% | 43.8% | ||
| Q4 24 | 6.0% | 43.0% | ||
| Q3 24 | 1.4% | 42.9% | ||
| Q2 24 | 1.3% | 44.5% | ||
| Q1 24 | -1.9% | 43.7% |
| Q4 25 | -2.9% | 25.3% | ||
| Q3 25 | -0.6% | 29.4% | ||
| Q2 25 | 6.4% | 32.8% | ||
| Q1 25 | -2.6% | 30.8% | ||
| Q4 24 | -3.8% | 28.6% | ||
| Q3 24 | -5.6% | 30.3% | ||
| Q2 24 | -3.6% | 43.0% | ||
| Q1 24 | -7.0% | 31.2% |
| Q4 25 | $-0.63 | $1.41 | ||
| Q3 25 | $-0.14 | $1.61 | ||
| Q2 25 | $1.43 | $1.81 | ||
| Q1 25 | $-0.63 | $1.65 | ||
| Q4 24 | $-0.97 | $1.50 | ||
| Q3 24 | $-1.35 | $1.54 | ||
| Q2 24 | $-0.88 | $2.15 | ||
| Q1 24 | $-1.63 | $1.52 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $2.2B |
| Total DebtLower is stronger | — | $3.2B |
| Stockholders' EquityBook value | $2.1B | $309.0M |
| Total Assets | $4.1B | $6.2B |
| Debt / EquityLower = less leverage | — | 10.45× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.2B | ||
| Q3 25 | — | $2.1B | ||
| Q2 25 | — | $628.7M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $308.6M | $291.2M | ||
| Q3 24 | $312.5M | $458.0M | ||
| Q2 24 | $302.6M | $632.1M | ||
| Q1 24 | $251.4M | $352.4M |
| Q4 25 | — | $3.2B | ||
| Q3 25 | — | $3.2B | ||
| Q2 25 | — | $3.2B | ||
| Q1 25 | — | $3.2B | ||
| Q4 24 | — | $2.5B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | — | $2.6B | ||
| Q1 24 | — | $2.9B |
| Q4 25 | $2.1B | $309.0M | ||
| Q3 25 | $2.1B | $376.7M | ||
| Q2 25 | $2.1B | $311.7M | ||
| Q1 25 | $2.0B | $123.0M | ||
| Q4 24 | $2.0B | $100.1M | ||
| Q3 24 | $2.0B | $299.6M | ||
| Q2 24 | $2.0B | $430.3M | ||
| Q1 24 | $2.1B | $282.2M |
| Q4 25 | $4.1B | $6.2B | ||
| Q3 25 | $4.1B | $6.2B | ||
| Q2 25 | $4.1B | $4.8B | ||
| Q1 25 | $4.2B | $5.1B | ||
| Q4 24 | $4.2B | $4.3B | ||
| Q3 24 | $4.3B | $4.6B | ||
| Q2 24 | $4.3B | $4.8B | ||
| Q1 24 | $4.3B | $4.5B |
| Q4 25 | — | 10.45× | ||
| Q3 25 | — | 8.57× | ||
| Q2 25 | — | 10.37× | ||
| Q1 25 | — | 26.30× | ||
| Q4 24 | — | 25.44× | ||
| Q3 24 | — | 8.50× | ||
| Q2 24 | — | 5.93× | ||
| Q1 24 | — | 10.14× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $60.6M | $343.3M |
| Free Cash FlowOCF − Capex | $36.0M | $276.1M |
| FCF MarginFCF / Revenue | 6.6% | 35.5% |
| Capex IntensityCapex / Revenue | 4.6% | 8.6% |
| Cash ConversionOCF / Net Profit | — | 1.74× |
| TTM Free Cash FlowTrailing 4 quarters | $91.8M | $1.2B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $60.6M | $343.3M | ||
| Q3 25 | $56.7M | $403.5M | ||
| Q2 25 | $11.2M | $244.5M | ||
| Q1 25 | $51.3M | $444.7M | ||
| Q4 24 | $40.2M | $263.9M | ||
| Q3 24 | $36.1M | $296.2M | ||
| Q2 24 | $82.0M | $211.7M | ||
| Q1 24 | $45.8M | $372.2M |
| Q4 25 | $36.0M | $276.1M | ||
| Q3 25 | $27.6M | $336.1M | ||
| Q2 25 | $-8.5M | $188.7M | ||
| Q1 25 | $36.7M | $391.0M | ||
| Q4 24 | $16.1M | $208.5M | ||
| Q3 24 | $16.2M | $240.7M | ||
| Q2 24 | $62.5M | $153.9M | ||
| Q1 24 | $29.9M | $317.0M |
| Q4 25 | 6.6% | 35.5% | ||
| Q3 25 | 5.1% | 43.7% | ||
| Q2 25 | -1.5% | 24.4% | ||
| Q1 25 | 6.1% | 51.9% | ||
| Q4 24 | 2.6% | 28.3% | ||
| Q3 24 | 2.7% | 33.2% | ||
| Q2 24 | 10.5% | 21.5% | ||
| Q1 24 | 5.3% | 45.0% |
| Q4 25 | 4.6% | 8.6% | ||
| Q3 25 | 5.4% | 8.8% | ||
| Q2 25 | 3.6% | 7.2% | ||
| Q1 25 | 2.4% | 7.1% | ||
| Q4 24 | 3.8% | 7.5% | ||
| Q3 24 | 3.4% | 7.7% | ||
| Q2 24 | 3.3% | 8.1% | ||
| Q1 24 | 2.8% | 7.8% |
| Q4 25 | — | 1.74× | ||
| Q3 25 | — | 1.79× | ||
| Q2 25 | 0.32× | 0.97× | ||
| Q1 25 | — | 1.91× | ||
| Q4 24 | — | 1.25× | ||
| Q3 24 | — | 1.35× | ||
| Q2 24 | — | 0.69× | ||
| Q1 24 | — | 1.69× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
VRSK
Segment breakdown not available.
